Validation of Sleep Measurements of an Actigraphy Watch: Instrument Validation Study.

Background: The iAide2 (Tokai) physical activity monitoring system includes diverse measurements and wireless features useful to researchers. The iAide2's sleep measurement capabilities have not been compared to validated sleep measurement standards in any published work.

Objective: We aimed to assess the iAide2's sleep duration and total sleep time (TST) measurement performance and perform calibration if needed.

On the Present Guideline-Focusing Points on FSCJ's Revised Guideline for the Risk Assessment of the Effects of Food on Health for Foodborne Microorganisms and Others (Viruses, Parasites) and Its Supplemental Technical Guidance.

Food Safety Commission of Japan (FSCJ) has recently revised the Guideline for the Risk Assessment of the Effects of Food on Health for Foodborne Microorganisms and Others (Viruses, Parasites) and newly issued its supplemental manual as the "Technical Guide for the Risk Assessment of the Effects of Food on Health for Foodborne Microorganisms and Others (Viruses, Parasites)". These documents are based recent evidence and according to the Microbiological Risk Assessment Guidance for Food, Microbiological Risk Assessment Series 36 published by FAO/WHO. This short review describes the main structures and characteristics of these documents.

On the Commemorative Ceremony and Symposium for the 20 Anniversary of Food Safety Commission, Cabinet Office, Government of Japan.

Food Safety Commission, Cabinet Office, Government of Japan (FSCJ) was established in 2003 and marked its 20 anniversary in 2023. FSCJ held a commemorative ceremony and symposium to celebrate its 20 anniversary at Mita conference hall (Mita, Minato-ku, Tokyo) on September 1st, 2023, which attracted a total of 164 on-site attendees including six media companies, as well as 460 online viewers. FSCJ Chairperson Dr.

Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.

A recent meta-analysis found no benefit of uric acid-lowering therapy including febuxostat on death, cardiovascular events, or renal impairment. However, there may be populations that benefit from febuxostat in reducing mortality and cerebral and cardiovascular events. The aim of the present study was to examine the clinical benefit of febuxostat in elderly patients stratified by age using Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED) data.